Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

TRJ. Evans, E. Van Cutsem, MJ. Moore, IS. Bazin, A. Rosemurgy, G. Bodoky, G. Deplanque, M. Harrison, B. Melichar, D. Pezet, A. Elekes, E. Rock, C. Lin, L. Strauss, PJ. O'Dwyer,

. 2017 ; 28 (2) : 354-361.

Language English Country Great Britain

Document type Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016847

Background: Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients with advanced PDAC. Dasatinib is a competitive inhibitor of Src kinase, which is overexpressed in PDAC tumors. Dasatinib and gemcitabine were combined in a phase 1 clinical trial where stable disease was achieved in two of eight patients with gemcitabine-refractory PDAC. Patients and methods: This placebo-controlled, randomized, double-blind, phase II study compared the combination of gemcitabine plus dasatinib to gemcitabine plus placebo in patients with locally advanced, non-metastatic PDAC. Patients received gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle combined with either 100 mg oral dasatinib or placebo tablets daily. The primary objective was overall survival (OS), with safety and progression-free survival (PFS) as secondary objectives. Exploratory endpoints included overall response rate, freedom from distant metastasis, pain and fatigue progression and response rate, and CA19-9 response rate. Results: There was no statistically significant difference in OS between the two treatment groups (HR = 1.16; 95% confidence interval [CI]: 0.81-1.65; P = 0.5656). Secondary and exploratory endpoint analyses also showed no statistically significant differences. The burden of toxicity was higher in the dasatinib arm. Conclusions: Dasatinib failed to show increased OS or PFS in patients with locally advanced PDAC. Alternative combinations or trial designs may show a role for src inhibition in PDAC treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016847
003      
CZ-PrNML
005      
20180515103446.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdw607 $2 doi
035    __
$a (PubMed)27998964
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Evans, T R J $u Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
245    10
$a Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer / $c TRJ. Evans, E. Van Cutsem, MJ. Moore, IS. Bazin, A. Rosemurgy, G. Bodoky, G. Deplanque, M. Harrison, B. Melichar, D. Pezet, A. Elekes, E. Rock, C. Lin, L. Strauss, PJ. O'Dwyer,
520    9_
$a Background: Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients with advanced PDAC. Dasatinib is a competitive inhibitor of Src kinase, which is overexpressed in PDAC tumors. Dasatinib and gemcitabine were combined in a phase 1 clinical trial where stable disease was achieved in two of eight patients with gemcitabine-refractory PDAC. Patients and methods: This placebo-controlled, randomized, double-blind, phase II study compared the combination of gemcitabine plus dasatinib to gemcitabine plus placebo in patients with locally advanced, non-metastatic PDAC. Patients received gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle combined with either 100 mg oral dasatinib or placebo tablets daily. The primary objective was overall survival (OS), with safety and progression-free survival (PFS) as secondary objectives. Exploratory endpoints included overall response rate, freedom from distant metastasis, pain and fatigue progression and response rate, and CA19-9 response rate. Results: There was no statistically significant difference in OS between the two treatment groups (HR = 1.16; 95% confidence interval [CI]: 0.81-1.65; P = 0.5656). Secondary and exploratory endpoint analyses also showed no statistically significant differences. The burden of toxicity was higher in the dasatinib arm. Conclusions: Dasatinib failed to show increased OS or PFS in patients with locally advanced PDAC. Alternative combinations or trial designs may show a role for src inhibition in PDAC treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a duktální karcinom slinivky břišní $x farmakoterapie $x mortalita $x patologie $7 D021441
650    _2
$a dasatinib $x aplikace a dávkování $7 D000069439
650    _2
$a deoxycytidin $x aplikace a dávkování $x analogy a deriváty $7 D003841
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory slinivky břišní $x farmakoterapie $x mortalita $x patologie $7 D010190
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Van Cutsem, E $u Department of Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
700    1_
$a Moore, M J $u Princess Margaret Cancer, Toronto, Canada.
700    1_
$a Bazin, I S $u Federal State Budgetary Institution, Dubna, Russia.
700    1_
$a Rosemurgy, A $u Surgery, Florida Hospital, Tampa, Tampa, USA.
700    1_
$a Bodoky, G $u Oncology, St.László Teaching Hospital, Budapest, Hungary.
700    1_
$a Deplanque, G $u Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
700    1_
$a Harrison, M $u East and North Hertfordshire NHS Trust, Northwood, Middlesex, UK.
700    1_
$a Melichar, B $u Department of Oncology, Lekarska Fakulta Univerzity Palackeho a Fakultni Nemocnice, Olomouc, Czech Republic.
700    1_
$a Pezet, D $u CHU Estaing, Clermont-Ferrand, France.
700    1_
$a Elekes, A $u Otsuka Pharmaceutical Development and Commercialization, Princeton.
700    1_
$a Rock, E $u Otsuka Pharmaceutical Development and Commercialization, Princeton.
700    1_
$a Lin, C $u Otsuka Pharmaceutical Development and Commercialization, Princeton.
700    1_
$a Strauss, L $u Bristol-Myers Squibb Company, Princeton.
700    1_
$a O'Dwyer, P J $u Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
773    0_
$w MED00000432 $t Annals of oncology official journal of the European Society for Medical Oncology $x 1569-8041 $g Roč. 28, č. 2 (2017), s. 354-361
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27998964 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103620 $b ABA008
999    __
$a ok $b bmc $g 1300471 $s 1013687
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 28 $c 2 $d 354-361 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options